Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
IBX Stock Chart & Stats
AU$0.03
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.03
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume347.18K
Average Volume (3M)16.05M
Market Cap
AU$10.30M
Enterprise ValueAU$5.36M
Total Cash (Recent Filing)AU$1.85M
Total Debt (Recent Filing)AU$2.56M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Addressable Oncology Imaging MarketThe company targets molecular imaging agents to improve cancer detection on standard clinical systems. This aligns with a durable, growing oncology diagnostics market and broad hospital imaging infrastructure, raising long-term commercial potential if clinical validation and reimbursement are achieved.
High Product-level Gross Margin SignalA reported ~85% gross margin in 2024 implies attractive unit economics for the imaging agent itself. If replicated at scale, high gross margins can support profitable operations once revenues ramp, allowing R&D and commercialization spend to leverage favorable product-level economics.
Improving Cash Outflow Trend In 2025Cash burn declined in 2025 versus 2024, indicating management has begun to curb outflows. Sustained reduction in cash burn can extend runway, improve chances of reaching clinical/commercial milestones without immediate dilutive financing, and reflect improving operational discipline.
Bears Say
Zero Revenue In 2025Revenue falling to zero in 2025 signals lack of commercial traction or transition to a pre-revenue profile. Without product sales, the company remains dependent on external funding; this undermines validation of market fit and prolongs the timeline to sustainable cash generation and profitability.
Negative Equity And Meaningful DebtNegative shareholders' equity since 2023 combined with multi-million dollar debt elevates solvency risk and constrains financial flexibility. This increases likelihood of dilutive financing or onerous terms, limits ability to absorb setbacks, and raises creditor priority over equity holders.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow (≈$4.0M burn in 2025) means ongoing reliance on financing to fund R&D and commercialization. Repeated capital raises risk dilution, can disrupt long-term planning, and may delay or prevent achieving the scale needed for self-sustaining operations.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$10.30M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 152 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 490,590,240 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
142.99%
Trailing 12-Months
Asset Growth
-27.09%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---